ZHEJIANG MEDICINE CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.15 CNY | 0.00% |
|
-1.93% | -14.73% |
| 2023 | Zhejiang Medicine Wins Nod to Trial Digestive Acid Drug | MT |
| 2023 | Zhejiang Medicine Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 | CI |
| Sales 2023 * | 8.08B 1.12B | Sales 2024 * | 9.71B 1.34B | Capitalization | 8.77B 1.21B |
|---|---|---|---|---|---|
| Net income 2023 * | 607M 83.76M | Net income 2024 * | 912M 126M | EV / Sales 2023 * | 1.08 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 0.9 x |
| P/E ratio 2023 * |
14.5
x | P/E ratio 2024 * |
9.63
x | Employees | 6,208 |
| Yield 2023 * |
2.08% | Yield 2024 * |
3.06% | Free-Float | 58.61% |
More Fundamentals
* Assessed data
More news
| 1 week | -1.93% | ||
| Current month | +2.35% | ||
| 1 month | -1.72% | ||
| 3 months | -3.89% | ||
| 6 months | -13.02% | ||
| Current year | -14.73% |
1 week
8.96
9.45
1 month
8.809.86
Current year
7.9710.98
1 year
7.9712.11
3 years
7.9721.16
5 years
7.9722.31
10 years
7.8122.31
| Managers | Title | Age | Since |
|---|---|---|---|
Chun Lei Lu
CEO | Chief Executive Officer | 57 | 06-05-31 |
Nan Xing Li
BRD | Director/Board Member | 38 | 15-06-10 |
Ke Qiu
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Chun Bo Li
CHM | Chairman | 65 | 97-04-30 |
Nai Wei Chen
BRD | Director/Board Member | 67 | 18-06-14 |
Chun Lei Lu
CEO | Chief Executive Officer | 57 | 06-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 31 M€ | +3.05% | - | |
| 0.00% | 34 M€ | +2.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 9.15 | 0.00% | 10,228,010 |
| 24-04-23 | 9.15 | -0.87% | 10,533,270 |
| 24-04-22 | 9.23 | -0.75% | 11,598,570 |
| 24-04-19 | 9.3 | +1.42% | 11,544,820 |
| 24-04-18 | 9.17 | -1.71% | 12,971,210 |
End-of-day quote Shanghai S.E., April 23, 2024
More quotes
Zhejiang Medicine Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of drugs and nourishments. The Company mainly provides nourishments for animals and human, health care products, and chemicals and chemical raw materials, among others. The Company's products include synthetic vitamin E, natural vitamin E soft capsules, Beta carotene, vancomycin hydrochloride for injection and teicoplanin for injection, among others. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
9.15
CNY
Average target price
13
CNY
Spread / Average Target
+42.08%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -14.73% | 1.21B | |
| +25.61% | 660B | |
| +24.15% | 562B | |
| -5.24% | 358B | |
| +16.49% | 322B | |
| +8.28% | 297B | |
| +12.45% | 219B | |
| -9.73% | 196B | |
| +6.40% | 199B | |
| -8.75% | 149B |
- Stock Market
- Equities
- 600216 Stock
